Диссертация (1145009), страница 65
Текст из файла (страница 65)
– N 90. – P. 244-48.372192. Blaser M.J. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach / M.J.Blaser, G.I. Perez-Perez, H. Kleanthous et all // Cancer Res. – 1995. – Vol. 55, N 10.– P. 2111-15.193. Blaser М. Ecology of Helicobacter pylori in human stomach / M. Blaser // J. Clin.Invest. – 1997. – N 100. – P.
759-62.194. Bliss С.М. Helicobacter pylori lipopolysaccharide binds to СD14 and stimulatesrelease of interleukin-8, epithelial neutrophil-activating peptide 78, and monocytechemotactic protein 1 by human monocytes / С.М. Bliss, D.Т. Golenbock, S.
Keates// Inlect. and Immun. – 1998. – N 66. – P. 5357-63.195. Bobryshev Y.V. Neovascular expression of VE-caderin in human atheroscleroticarteries and its relation to intimai inflammation / Y.V. Bobryshev, S.M. Cherian, S.J.Inder et all // Cardiovasc. Research. – 1999. – Vol.
43, N 4. – P. 1003-17.196. Bonaterra G.А. Novel systemic cardiovascular disease biomarkers / G.А.Bonaterra, S. Zugel, R. Kinscherf // Сurr. Mol. Med. – 2010. – N 10. – P. 180-205.197. Borlace G.N. Monocyte and macrophage killing of helicobacter pylori: relationshipto bacterial virulence factors / G.N. Borlace, R.N.
Butler, D.A. Brooks // Helicobacter. – 2008. – Vol. 13, N 5. – P. 380-87.198. Bourcier T. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells / T.Bourcier, P. Libby // Arterioscler. Thromb. Vasc. Biol. – 2000. – N 20. – P. 556-62.199. Boushey C.J. A quantitive assessment of plasma homocysteine as a risk factor forvascular disease: probable benefits of increasing folic acid intakes / C.J. Boushey,S.A.A. Beresford, G.S. Omenn et all // JAMA.
– 1995. – Vol. 274, N 13. – P. 104957.200. Boyd J.H. Toll-like receptor stimulation in cardiomyocytes decreased contractilityand initiates an NF-κB dependent inflammatory response / J.H. Boyd, S. Mathur, T.Wang et all // Cardiovasc. Res. – 2006. – Vol. 72, N 3. – P. 384-93.373201. Brandtzaeg P. Overwiew of the mucosal immune system / P. Brandtzaeg // Curr.Top. Microbiol. Immunol.
– 1989. – N 146. – P. 13-25.202. Braunwald E. Diagnosing and Managing Unstable Angina / E. Braunwald, R.H.Jones, D.B. Mark // Circulation. – 1994. – N 89. – P. 1449-68.203. Brisslert M. Helicobacter pylori induce neutrophil transendothelial migration: roleof the bacterial HP-NAP / M. Brisslert, K. Enarsson, S. Lundin et all // FEMSMicrobiol.
Lett. – 2005. – N 249. – P. 95-103.204. Buechler C. Lipoprotein(a) down regulates lysosomal acid lipase and inducesinterleukine-6 in human blood monocytes / C. Buechler, H. Vilrich, C. Aslanidis etall // Biochim. Biophys. Acta. – 2003. – Vol. 1642, N 1-2. – P. 25-31.205. Byrne M.F. Helicobacter pylori induces cyclooxygenase-1 and cyclooxygenase-2expression in vascular endothelial cells / M.F. Byrne, J.F. Murphy, P.A.
Corcoran etall // Scand. J. Gastroenterol. – 2003. – N 38. – P. 1023-30.206. Cai X.J. Study on the correlation of between infection, inflammation and coronaryartery disease / X.J. Cai, H.B. Cai, D. Lu // Zhonghua Liu Xing Bing Xue Za Zhi. –2003. – Vol. 24, N 6. – P. 503-507.207. Cai Н. Endothelial dysfunction in cardiovascular disease: the role of oxidant stress/ Н. Cai, D.G. Harrison // Circ Res. – 2000. – N 87. – P. 840-44.208. Caligiuri G. Chlamydia pneumoniae infection does not induce or modifies atherosclerosis in mice / G.
Caligiuri, M. Rottenberg, A. Nicoletti et all // Circulation. –2001. – N 103. – P. 2834-38.209. Caligiuri G. IL-10 deficiency increases atherosclerosis, thrombosis and LDL inapolipoprotein E-knockout mice / G. Caligiuri, M. Rudling, V. Ollivier et all // Mol.Med. – 2003. – N 9. – P. 10-17.210. Cannon C.P. Antibiotic treatment of chlamydia pneumoniae after acute coronarysyndrome / C.P. Cannon, E.
Braunwald, C.H. McCabe et all // N. Engl. J. Med. –2005. – N 352. – P. 1646-54.374211. Caruso R. IL-23-mediated regulation of IL-17 production in Helicobacter pyloriinfected gastric mucosa / R. Caruso, D. Fina, O.A. Paoluzi et all // Eur. J. Immunol.– 2008. – N 38. – P. 470-78.212. Chao C. The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women:the Women's Health Initiative Observational Study / C.
Chao, Y. Song, N. Cook etall // Arch. Intern. Med. – 2010. – Vol. 170, N 17. – P. 1557-65.213. Charo I.F. The many roles of chemokines and chemokine receptors in inflammation / I.F. Charo, R.M. Ransohoff // N. Engl. J. Med. – 2006. – N 354. – P. 610-21.214.
Chen T.S. Immunoglobulin G antibody against Helicobacter pylori: clinical implications of levels found in serum / T.S. Chen, F.Y. Li, F.Y. Chang, S.D. Lee // Clin.Diagn. Lab. Immunol. – 2002. – Vol. 9, N 5. – P. 1044-48.215. Chen X.H. Prevalence of H. pylori infection in acute coronary syndrome patientsand the association between H. pylori infection and acute coronary syndrome / X.H.Chen, Y.S. Wang, J.B. Wang // Chin.
J. Crit. Care Med. (Chin) – 2007. – N 27. – P.385-88.216. Cheng G.C. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathologic correlation / G.C. Cheng,H.M. Loree, R.D. Kamm et all // Circulation. – 1993. – N 87. – P. 1179-87.217. Ching C.K. Prevalence of CagA-bearing Helicobacter pylori strains detected by theanti-CagA assay in patients with peptic ulcer disease and in controls / C.K.
Ching,B.C. Wong, E. Kwok et all // Am. J. Gastroenterol. – 1996. – Vol. 91, N 5. – P. 94953.218. Chmiela М. Enhanced humoral response to Н.pylori or/and Chlamydia spp. as аdistinctive trait of patients with coronary heart disease (CHD) / М. Chmiela, М.Wisniewska, A. Miszczak et all // Gut. – 2002. – N 51(Supp1.2). – P. А77.219.
Chui B. Chlamydia pneumoniae, cytomegalovirus and Herpes simplex virus / B.Chui, E. Viira, B. Tucker, I. Fong // Circulation. – 1997. – N 96. – P. 2144-48.375220. Cohen М.С. Cytokine function / М.С. Cohen, S. Cohen // Am. J. Clin. Pathol. –1996. – N 105. – P. 589-98.221. Cooke J.P. Biomarkers of peripheral arterial disease / J.P. Cooke, A.M.
Wilson // J.Am. Coll. Cardiol. – 2010. – Vol. 55, N 19. – P. 2017-23.222. Cooper A.M. IL-17 and anti-bacterial immunity: protection versus tissue damage /A.M. Cooper // Eur. J. Immunol. – 2009. – N 39. – P. 649-52.223. Corrado E. Role of inflammation and infection in vascular disease / E. Corrado, S.Novo // Acta Chir. Belg. – 2005. – N 105. – P.
567-79.224. Covacci A. Molecular characterization of the 128-kDa immunodominant antigenof Helicobacter pylori associated with cytotoxicity and duodenal ulcer / A. Covacci,S. Censini, M. Bugnoli et all // Proc. Natl. Acad. Sci. USA. – 1993. – N 90. – P.5791-95.225. Crabtree J.E. Mucosal tumour necrosis factor alpha and interleukin-6 in patientswith Helicobacter pylori associated gastritis / J.E. Crabtree, T.M. Shallcross, R.V.Heatley, J.I. Wyatt // Gut. – 1991. – N 32. – P. 1473-77.226. Crabtree J.Е. Immune and inflammatory responses to Helicobacter pylori infection/ J.Е. Crabtree // Scand. J.
Gastroenterol. – 1996. – Vol. 31, s215. – P. 3-10.227. Croce K. Intertwining of thrombosis and inflammation in atherosclerosis / K. Croce, P. Libby // Curr. Opin. Hematol. – 2007. – N 14. – P. 55-61.228. D’Elios M.M. Gastric autoimmunity: the role of Helicobacter pylori and molecularmimicry / M.M. D’Elios, B.J. Appelmelk, A. Amedei, M.P. Bergman, G.
Del Prete// Trends Mol. Med. – 2004. – N 10. – P. 316-23.229. D’Elios M.M. Different cytokine profile and antigen-specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patientswith or without peptic ulcer / M.M. D’Elios, M. Manghetti, F. Almerigogna et all //Eur.
J. Immunol. – 1997. – Vol. 27, N 7. – P. 1751-55.376230. D’Elios M.M. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease / M.M. D’Elios, M. Manghetti, M.De Carli, F. Costa et all // J. Immunol. – 1997. – N 158. – P. 962-67.231. Dallmeier D. Metabolic Syndrome and Inflammatory Biomarkers: a communitybased cross-sectional Study at the Framingham Heart Study / D. Dallmeier, M.
Larson, R. Vasan et all // Diabetol. Metab. Syndr. – 2012. – Vol. 4, N 1. – P. 28.232. Danesh J. Association of fibrinogen, C-reactive protein, albumin, or leukocytecount with coronary heart disease: meta-analyses of prospective studies / J.
Danesh,R. Collins, P. Appleby, R. Peto // JAMA. – 1998. – N 279. – P. 1477-82.233. Danesh J. Chronic infections and coronary heart disease: is there a link? / J.Danesh, R. Collins, R. Peto // Lancet. – 1997. – N 350. – P. 430-36.234. Danesh J. C-reactive protein and other circulating markers of inflammation in theprediction of coronary heart disease / J. Danesh, J.G. Wheeler, G.M. Hirschfield etall // N. Engl. J. Med. – 2004. – N 350. – P.
1387-97.235. Danesh J. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, orCytomegalovirus: population based study of coronary heart disease / J. Danesh, Y.Wong, M. Ward et all // Heart. – 1999. – N 81. – P. 245-47.236. Danesh J. Helicobacter plori infection and early onset myocardial infarction: casecontrol and sibling pairs study / J. Danesh, L. Youngmann, S.
Clark et all // Br. Med.J. – 1999. – N 319. – P. 1157-62.237. Davey Smith G. C-reactive protein and cardiovascular disease risk: still an unknown quantity? / G. Davey Smith, N. Timpson, D.A. Lawlor // Ann. Intern. Med.2006; 145: 70-72.238. Davi G.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
